C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the ...
C4 Therapeutics announced an abstract with preliminary Phase 1 CFT1946 data for mutant BRAF V600 solid tumors, available on the ESMO Congress 2024 website. An oral presentation on September 13, 2024, will update data on 36 patients, including safety, pharmacokinetic, pharmacodynamic, and anti-tumor activity data. A webcast for analysts and investors will discuss these findings at 12:00 pm ET.
Related Clinical Trials
Highlighted Terms
Related News
C4 Therapeutics announced an abstract with preliminary Phase 1 CFT1946 data for mutant BRAF V600 solid tumors, available on the ESMO Congress 2024 website. An oral presentation on September 13, 2024, will update data on 36 patients, including safety, pharmacokinetic, pharmacodynamic, and anti-tumor activity data. A webcast for analysts and investors will discuss these findings at 12:00 pm ET.
CFT1946, an orally bioavailable BRAF V600 mutant degrader, shows well-tolerated safety profile, dose-dependent bioavailability, and initial anti-tumor activity in solid tumors, with no dose-limiting toxicities. The Phase 1 trial continues to enroll patients, with additional data expected in 2025.
C4 Therapeutics announced the release of a clinical trial abstract for CFT1946, a BiDAC™ degrader for BRAF V600 solid tumors, at ESMO Congress 2024. Data from 36 patients will be presented on September 13, 2024, followed by a webcast for investors.